Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
Holding ALMS?
Track your performance easily
ALMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.23 - $13.53
Previous Close$9.46
Volume120.50K
Average Volume (3M)152.05K
Market Cap
$514.69M
Enterprise Value$183.92M
Total Cash (Recent Filing)$361.87M
Total Debt (Recent Filing)$31.10M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 13, 2024EPS Estimate
-$1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.47
Shares Outstanding54,407,327
10 Day Avg. Volume130,743
30 Day Avg. Volume152,046
Standard Deviation0.10
R-Squared0.27
Alpha0.00384
Financial Highlights & Ratios
Price to Book (P/B)1.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.30
Forecast
1Y Price Target
$30.50Price Target Upside222.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Alumis Inc. News
PremiumCompany Announcements
Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAlumis' Phase 2 STRIDE study in moderate-to-severe psoriasis showed compelling results, including week 12 induction data which appears competitive to alternative oral therapeutics.
Product DevelopmentAlumis is working on a once-daily formulation for ESK-001, which will be important for the convenience aspect of the product profile.
Product PotentialAnalyst's recommendation is based on the view that Alumis has two differentiated TYK2 inhibitors in development, each with blockbuster potential across I&I and neuroinflammatory conditions.
Bears Say
Clinical Trial PerformanceTopline data from icotrokinra’s Phase 3 ICONIC-LEAD trial underperformed some investor expectations to observe efficacy in the range of injectable IL-23s.
Product ValuationA-005 accounts for very little of the current valuation due to uncertainty around the validity of the mechanism and lack of in-human data.
Trial MethodologyIf a patient discontinued due to an adverse event or inadequate response, they were imputed as a non-responder.
---
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $8.22 and its highest was $13.53 in the past 12 months.
What is Alumis Inc.’s market cap?
Currently, no data Available
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Nov 13, 2024 which is 10 days ago.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Aug 13, 2024. The company reported -$1.47 earnings per share for the quarter, missing the consensus estimate of -$1.46 by -$0.01.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -$1.78.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 47,222,420 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$1.47 in its last earnings report, missing expectations of -$1.46. Following the earnings report the stock price went down -12.951%.
Which hedge fund is a major shareholder of Alumis Inc.?
Among the largest hedge funds holding Alumis Inc.’s share is Baker Bros Advisors LP. It holds Alumis Inc.’s shares valued at 17M.
---
Alumis Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Alumis Inc.
Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively.
---
ALMS Stock 12 Month Forecast
Average Price Target
$30.50
▲(222.41% Upside)
Technical Analysis
Best Analysts Covering ALMS
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-2.60%
reiterated a buy rating 9 days ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -2.60% per trade.
---